Diabetes cell therapy by human islet transplantation can restore an endogenous insulin secretion and normal glycaemic control in type 1 diabetic patients for as long as 10 years post transplantation. Before transplantation, each clinical islet preparation undergoes extensive and quality controls. The quality control assay consists of transplanting human islets under the kidney capsule of immunocompromised mice. Currently, it is considered the best predictive factor to qualify clinical transplant efficiency. This chimeric model offers a wide area of study since it combines the possibility of producing not only quantitative but also a maximum of qualitative data. Today's technological advances allow us to obtain more accurate and stronger data from the animals used in research while ensuring their comfort and well-being throughout the protocol, including cage enrichment and pain treatment during and after surgery. As demonstrated in this valuable model, we are able to generate more usable results (Refine), while reducing the number of animals used (Reduce), by focusing on the development of analysis techniques (Replace), which clearly highlights the Burch and Russell 3Rs concept.

Download full-text PDF

Source
http://dx.doi.org/10.1177/00236772211004051DOI Listing

Publication Analysis

Top Keywords

islet transplantation
8
kidney capsule
8
pancreatic islet
4
transplantation
4
transplantation kidney
4
capsule mice
4
mice model
4
model refinement
4
refinement molecular
4
molecular graft
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!